10-Q: Cryomass Technologies Reports Q1 2024 Results with Revenue Growth but Continued Losses

Cryomass Technologies saw a small increase in revenue but continued to experience net losses in the first quarter of 2024, alongside ongoing concerns about its ability to continue as a going concern.

Summary

• Cryomass Technologies reported a net loss of $2,554,469 for the three months ended March 31, 2024, compared to a net loss of $1,598,526 for the same period in 2023.
• The company generated $5,300 in revenue during the quarter, a significant increase from no revenue in the prior year's comparable quarter.
• Operating expenses decreased by 31% to $1,056,773, primarily due to lower personnel costs and legal fees.
• The company's total liabilities significantly exceed its assets, resulting in a working capital deficit of $3,330,335.
• Cryomass has an accumulated deficit of $54,521,725 since inception.
• The company's cash balance at the end of the quarter was $23,922, down from $49,224 at the beginning of the period.
• A contingent royalty liability of $2,546,000 was recorded, reflecting a 10% net revenue sharing agreement with CRYM Co-Invest.
• The company believes it needs approximately $3,200,000 to cover overhead costs and up to $3,125,000 for capital expenditures based on current customer activity.
• Cryomass is dependent on future equipment sales, royalty payments, and additional financing to continue operations.

Sentiment

Score: 3

Explanation: The document indicates significant financial challenges, including a large net loss, low cash reserves, and concerns about the company's ability to continue as a going concern. While there are some positive developments, the overall sentiment is negative due to the company's precarious financial situation and ineffective internal controls.

Positives

• The company generated $5,300 in revenue, marking a significant improvement from the prior year.
• Operating expenses decreased by 31%, indicating cost-cutting measures are taking effect.
• The company has secured a purchase agreement for one CryoSift Separator Unit for $1.2 million, with a lease agreement in place.

Negatives

• The company experienced a net loss of $2,554,469, an increase from the prior year's loss.
• The company has a significant working capital deficit of $3,330,335.
• The cash balance is very low at $23,922, raising concerns about liquidity.
• There is substantial doubt about the company's ability to continue as a going concern.
• The company has a large accumulated deficit of $54,521,725.
• The company's disclosure controls and procedures were deemed ineffective due to significant deficiencies in internal control over financial reporting.

Risks

• The company's ability to continue as a going concern is highly uncertain, depending on future revenue and financing.
• The company has a significant working capital deficit and low cash reserves.
• The company is incurring substantial losses and has a large accumulated deficit.
• The company's internal controls over financial reporting are ineffective, which could lead to misstatements in financial reports.
• The company is dependent on a limited number of agreements for revenue generation.
• The company faces risks related to the cannabis and cannabinoid industries, including regulatory changes and competition.

Future Outlook

The company expects to finance future cash needs from the results of operations and additional financing until the company can achieve profitability and positive cash flows from operating activities. However, there is no assurance that the company will receive sufficient cash flow from operations or be able to attract the necessary financing.

Management Comments

• Management believes that the company's available cash balance will not be sufficient to fund its anticipated level of operations for at least the next twelve months.
• Management believes that the company's ability to continue operations depends on cash expected to be available from planned equipment sales and royalty payments, or possibly from debt or equity investments.
• Management has concluded that the company did not maintain effective internal control over financial reporting as of the quarter ended March 31, 2024.

Industry Context

Cryomass operates in the cannabis and hemp industry, which is experiencing growth due to increasing acceptance of medicinal cannabis products and anticipated legislative changes. The company's technology aims to improve post-harvest methods, potentially leading to industry-wide shifts.

Comparison to Industry Standards

• It is difficult to directly compare Cryomass to industry standards due to its unique technology and early stage of commercialization.
• Companies like Aurora Cannabis, Canopy Growth, and Tilray are larger, established players in the cannabis industry, but they focus on cultivation and processing rather than specialized equipment like Cryomass.
• Cryomass's technology is focused on trichome separation, which is a niche area within the broader cannabis industry, making direct comparisons challenging.
• The company's financial results are significantly weaker than those of established cannabis companies, reflecting its early stage and high operating costs.
• The company's reliance on a limited number of agreements for revenue generation is a risk compared to more diversified companies.

Related Party Transactions

• The company has a loan agreement with CRYM Co-Invest, where Alexander Massa, a 23.1% beneficial owner, has investment control.
• The company received loans from directors Simon Langelier and Mario Gobbo, and from Health Diplomats Pte Ltd, where director Dr. Delon Human is the President.
• The company's CEO, Christian Noel, joined the board of directors of RubberRock, creating a related party disclosure requirement, which ended in January 2024.

Stakeholder Impact

• Shareholders face significant risk due to the company's financial instability and going concern uncertainty.
• Employees may be impacted by potential cost-cutting measures or the company's inability to continue operations.
• Customers may be affected by the company's ability to deliver products and services.
• Creditors face the risk of non-payment due to the company's financial difficulties.
• Suppliers may be impacted by the company's ability to pay for goods and services.

Next Steps

• The company intends to continue to evaluate and strengthen its internal control over financial reporting.
• Management intends to develop or improve procedures to address the current significant deficiencies.
• The company will continue to seek additional financing to fund its operations.
• The company will focus on generating revenue from equipment sales and royalty payments.

Key Dates

Keywords

Cryomass, cannabis, hemp, trichome separation, cryogenic, revenue, net loss, financial results, going concern, internal controls, CryoSift Separator, royalty, deferred revenue